Reading OPRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OPRX free→Reading OPRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OPRX free→
NASDAQHealth CareHealth Information ServicesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong. Earnings quality is robust, but management's track record is volatile. Risk is elevated, and the sector backdrop is a headwind. Peer multiples imply a price about 57% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk. This pattern suggests potential issues due to weak financials or fragile earnings quality. The read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 5 valuation methods, at three horizons. Current price $5.23. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $5.23 OPRX trades at 6× p/e, below its 15× p/e peer median. Our $12 fair value sits above the price; medium confidence. Analysts: $7.00–$17. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 57% below a flat-multiple fair value, below our forecast of about 17%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 2.10x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.00 → $0.11. 0 raised, 1 cut, 5 covering analysts.
0 upgrades, 0 downgrades / 30d. 86% of analysts rate Buy.
0 positive, 0 negative / 30d.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$294.
How much price usually moves either way.
On a bad day, this stock has moved -$712.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,772.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: This will indicate if the company can achieve its adjusted EBITDA guidance of $21M-$25M for 2026.
Confirms one read:Adjusted EBITDA was at or above $23M. This is the midpoint of guidance.
Confirms the other:Adjusted EBITDA was below $21M. This shows they did not meet guidance.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for OPRX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 9, 2026, at the OptimizeRx Corporation (the “Company”) 2026 Annual Meeting of Shareholders (“Annual Meeting”) , shareholders approved an amendment (the “Amendment No. 2”) to the OptimizeRx Corporation 2021 Equity Incentive Plan (the “Equity Plan”) to increase the number of shares of common stock (“Common Stock”) available for awards under t…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
$7.00 – $17.00 (median $11.00) · 5 analysts · as of 2026-05-13
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Technology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
OPRX OptimizeRx Corp. | Typical Show detailsSector percentile: 34 of 100 | inexpensive | elevated |
VEEV Veeva Systems | Above typical Show detailsSector percentile: 79 of 100 | full | elevated |
SOLV Solventum | Above typical Show detailsSector percentile: 73 of 100 | fair | moderate |
TEM TEMPUS AI, INC. | Above typical Show detailsSector percentile: 73 of 100 | — | elevated |
DOCS Doximity | Above typical Show detailsSector percentile: 80 of 100 | full | high |
9 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
OptimizeRx aims to achieve its revenue guidance of $109 million to $114 million for fiscal year 2026.
OptimizeRx aims to achieve its adjusted EBITDA guidance of $21 million to $25 million for fiscal year 2026.
OptimizeRx is focused on improving cash from operating activities, which was negative in 2026-Q1.
Why it matters: This report will show if the company meets its revenue guidance of $109M-$114M for 2026.
Confirms one read:Q2 revenue reported at or above $111M, which is the midpoint of guidance.
Confirms the other:Q2 revenue was below $109M. This shows they did not meet guidance.
Why it matters: Improving cash from operations is key for the company's financial health and growth.
Confirms:Cash from operating activities is getting better. It goes up every quarter.
Disproves:Cash from operating activities is going down or staying the same. This shows problems.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As previously disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, OptimizeRx Corporation (the “Company”) and Theresa Greco agreed on May 11, 2026 to a separation, effective as of June 15, 2026 (the “Separation Date”). Accordingly, effective as of the Separation Date, Ms. Greco will no longer serve as the C…
and Exhibit 99.1 attached hereto are furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Entry into a Material Definitive Agreement. On May 7, 2026 (the “Closing Date”), OptimizeRx Corporation, a Nevada corporation (the “Company” or “Borrower”), entered into a credit agreement (the “Credit Agreement”) with the other loan parties from time to time party thereto (the “Loan Parties”), the lenders from time to time party thereto (the “Lenders”), and Fifth Third Bank, National Association (“Fifth Third”), as Agent, L/C Issuer and Swing Line Lender. Fifth Third also acted as Sole Lead…
Termination of a Material Definitive Agreement. The information included in